From: The fraction of sensitization among lung transplant recipients in a transplant center in Japan
Total (n = 93) | PRA+ (n = 23) | PRA- (n = 70) | p-value | |
---|---|---|---|---|
Age at LTX, median (IQR) | 42 (32–50) | 45 (33–50) | 41 (31–49) | 0.423 |
Sex, female | 53 (57.0%) | 13 (56.5%) | 40 (75.5%) | 1.000 |
LTX procedure | ||||
Single | 48 (51.6%) | 11 (47.8%) | 37 (52.9%) | 0.935 |
Double | 37 (39.8%) | 10 (43.5%) | 27 (38.6%) | |
Living-donor | 8 (8.6%) | 2 (8.7%) | 6 (8.6%) | |
LTX indication | ||||
Pulmonary vascular disease | 21 (22.6%) | 4 (17.4%) | 17 (24.3%) | 0.282 |
Restrictive lung disease | 19 (20.4%) | 7 (30.4%) | 12 (17.1%) | |
Obstructive lung disease | 39 (41.9%) | 7 (30.4%) | 32 (45.7%) | |
Suppurative lung disease | 8 (8.6%) | 4 (17.4%) | 4 (5.7%) | |
CLAD | 2 (2.2%) | 0 (0%) | 2 (2.9%) | |
Others | 4 (4.3%) | 1 (4.3%) | 3 (4.3%) | |
Pre-LTX comorbidities | ||||
Diabetes | 6 (6.5%) | 1 (4.3%) | 5 (7.1%) | 1.000 |
Connective tissue disease | 14 (15.1%) | 6 (23.1%) | 8 (11.4%) | 0.102 |
GERD | 5 (12.8%) | 2 (8.7%) | 3 (4.3%) | 0.594 |
Chronic kidney diseasea | 3 (3.3%) | 1 (4.3%) | 2 (2.9%) | 1.000 |